During the 2023 American Society of Clinical Oncology Annual Meeting, the Lymphoma Hub spoke with Swetha Kambhampati, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, How effective is chimeric antigen receptor T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL) in a standard-of-care setting?
Kambhampati discusses results from a prospective, non-interventional cohort study of patients with MCL who are treated with brexucabtagene autoleucel from the Center for International Blood & Marrow Transplant Research registry. Kambhampati compares these data to the ZUMA-2 trial and highlights the comparable efficacy and safety of brexucabtagene autoleucel, regardless of prior transplant or Bruton’s tyrosine kinase inhibitor therapy.
Visit www.lymphomahub.com for more information on this topic.
